Loading clinical trials...
Loading clinical trials...
A Randomized, Double Blind, Placebo Controlled Phase II Trial to Evaluate the Safety and Efficacy of recMAGE-A3 + AS15 ASCI in Patients With MAGE-A3 Positive Muscle Invasive Bladder Cancer After Cystectomy
Conditions
Interventions
recMAGE-A3 + AS15 ASCI
Placebo
Locations
50
Czechia
Faculty teaching Hospital in Plzen
Pilsen, Czechia
Hospital Motol
Prague, Czechia
Thomayerova nemocnice
Prague, Czechia
Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem, o.z.
Ústí nad Labem, Czechia
Institut Bergonié
Bordeaux, France
Hôpital Huriez
Lille, France
Start Date
August 1, 2011
Primary Completion Date
April 7, 2017
Completion Date
April 7, 2017
Last Updated
January 9, 2019
NCT07222488
NCT05614739
NCT06441110
NCT06403202
NCT03459846
NCT02489890
Lead Sponsor
European Association of Urology Research Foundation
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions